Purpose of this Study
We are doing this study to learn more about ATTR and its different variants and how they can can be better diagnosed, managed, and treated.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with ATTR
- Do not have primary or light chain amyloidosis
- Are not enrolled in an interventional clinical trial
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you want to participate in the study, it will not involve any type of experimental drug or other intervention. We will ask you to fill out surveys about your health about every 6 months at your routine clinic appointments. We will collect this information from you for up to 7 years.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
Yes
Study Details
Full Title
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Amyloid Transthyretin (ATTR) Amyloidosis
Principal Investigator
Michel
Khouri
Protocol Number
PRO00115927
Phase
N/A
Enrollment Status
Open to Enrollment